Pharmacoepigenetics and pharmacoepigenomics

Pharmacogenomics

Volumn 9, Issue 12, 2008, Pages 1785-1786

  Peedicayil, Jacob ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DNA; DNA METHYLTRANSFERASE INHIBITOR; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; HISTONE METHYLTRANSFERASE; MICRORNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

CARCINOGENICITY; DNA METHYLATION; DNA SEQUENCE; DRUG APPROVAL; EDITORIAL; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC DISORDER; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PATHOGENESIS; PHARMACOGENETICS; PHARMACOGENOMICS; RNA INTERFERENCE; TOXICOGENETICS; GENETIC EPIGENESIS; METHODOLOGY;

EPIGENESIS, GENETIC; HUMANS; PHARMACOGENETICS;

EID: 61549097508     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.12.1785     Document Type: Editorial

References (19)

1. Shurin SB, Nabel EG: Pharmacogenomics - ready for prime time? N. Engl. J. Med. 358(10), 1061-1063 (2008).
2. Peedicayil J: Epigenetic therapy - a new development in pharmacology. Indian J. Med. Res. 123(1), 17-24 (2006).
3. The American Association for Cancer Research Human Epigenome Task Force and the European Union, Network of Excellence, Scientific Advisory Board: Moving AHEAD with an international human epigenome project. Nature 454, 711-715 (2008).
4. Szyf M: Toward a discipline of pharmacoepigenomics. Curr. Pharmacogenomics 2(4), 357-377 (2004). (Pubitemid 39561840)
5. Feinberg AP: Epigenetics at the epicenter of modern medicine. JAMA 299(11), 1345-1350 (2008).
6. Feinberg AP: Phenotypic plasticity and the epigenetics of human disease. Nature 447, 433-440 (2007).
7. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116(3), 496-526 (2007). (Pubitemid 350116943)
8. Bonetta L: Epigenomics: detailed analysis. Nature 454, 795-800 (2008).
9. Gal-Yam EN, Saito Y, Egger G, Jones PA: Cancer epigenetics: modifications, screening, and therapy. Annu. Rev. Med. 59, 267-280 (2008). (Pubitemid 351287937)
10. Kristeleit R, Stimson L, Workman P, Aherne W: Histone modification enzymes: novel targets for cancer drugs. Expert Opin. Emerg. Drugs 9(1), 135-154 (2004). (Pubitemid 38715582)
11. Grosshans H, Filipowicz W: Molecular biology: the expanding world of small RNAs. Nature 451, 414-416 (2008). (Pubitemid 351158877)
12. Zhang B, Farwell MA: microRNAs: a new emerging class of players for disease diagnostics and gene therapy. J. Cell. Mol. Med. 12 (1), 3-21 (2008).
13. Kim DH, Rossi JJ: RNAi mechanisms and applications. Biotechniques 44(5), 613-616 (2008).
14. Hannon GJ, Rossi JJ: Unlocking the potential of the human genome with RNA interference. Nature 431, 371-378 (2004). (Pubitemid 39265678)
15. Haussecker D: The business of RNAi therapeutics. Hum. Gene Ther. 19(5), 451-462 (2008). (Pubitemid 351748790)
16. Adcock IM: HDAC inhibitors as antiinflammatory agents. Br. J. Pharmacol. 150(7), 829-831 (2007).
17. Watson RE, Goodman JI: Epigenetics and DNA methylation come of age in toxicology. Toxicol. Sci. 67(1), 11-16 (2002).
18. Orphanides G, Kimber I: Toxicogenetics: applications and opportunities. Toxicol. Sci. 75(1), 1-6 (2003). (Pubitemid 37098729)
19. Hamadeh HK, Amin RP, Paules RS, Afshari CA: An overview of toxicogenomics. Curr. Issues. Mol. Biol. 4(2), 45-56 (2002).